Breathing Labs
Home
How To Start
Products
Breathing+ Package
Toys Package
Q&A
Login

Idiopathic Pulmonary Fibrosis

20Dec

PIRFENIDONE 200MG TABLET Manufacturer, Supplier, Exporter

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on PIRFENIDONE 200MG TABLET Manufacturer, Supplier, Exporter

Product Description BENEFITS OF PIRMAX TABLET In Treatment of Idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These […]

Read more
18Dec

Pirfenidone | Horizonscan geneesmiddelen

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone | Horizonscan geneesmiddelen

Pirfenidone | Horizonscan geneesmiddelen www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies op www.rijkshuisstijl.nlSluiten Extended indication Extension of indication to include the treatment of unclassifiable interstitial lung disease (UILD) for Esbrie. Therapeutic value No estimate possible yet Registration phase No registration expected Product […]

Read more
18Dec

Nintedanib Ethanesulfonate Salt CAS:656247-18-6 – Yunfei Pharmaceutical (Shenzhen) Co.,Ltd

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Nintedanib Ethanesulfonate Salt CAS:656247-18-6 – Yunfei Pharmaceutical (Shenzhen) Co.,Ltd

Model: CAS:656247-18-6 About Nintedanib Ethanesulfonate Salt:CERTIFICATE OF ANALYSIS Product Name Nintedanib Ethanesulfonate Salt Batch No. 20210401 Mfg Date 2021.04.17 Quantity 15.190kg Exp Date 2023.04.16 CAS 656247-18-6 Report Date 2021.04.18 Items Specifications Results Appearance Yellow to yellow green powder Yellow green powder Water 1.0-2.0% 1.4% Residue on ignition ̤0.20% 0.04% Related substances Individual impurity̤0.1% 0.05% Total […]

Read more
18Dec

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib – Fingerprint — Experts@Minnesota Sort by Weight Alphabetically Medicine & Life Sciences nintedanib 100% Idiopathic Pulmonary Fibrosis 75% Comorbidity 48% P-glycoprotein 2 19% Pragmatic Clinical Trials 17% Pulmonologists 17% Cytochrome P-450 CYP3A 14% Anticoagulants 11% […]

Read more
17Dec

Evaluation of role of interferon gamma release assays in the diagnosis of latent tuberculosis in human immunodeficiency virus-infected patients

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Evaluation of role of interferon gamma release assays in the diagnosis of latent tuberculosis in human immunodeficiency virus-infected patients

Introduction: Tuberculosis (TB) is the most common opportunistic infection in human immunodeficiency virus (HIV)-infected individuals. The risk of eventually developing active TB from latent TB infection (LTBI) is about 10% per year in HIV-positive patients in contrast to 10% lifetime risk in HIV-negative patients. Until recently, the tuberculin skin test (TST) was the only tool […]

Read more
15Dec

Pirfenidone Tablet | 001 Ivermectin Store

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone Tablet | 001 Ivermectin Store

Ziverdo Kit Store’s sole intention is to ensure that its consumers get expert-reviewed, accurate, and trustworthy information. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions, […]

Read more
15Dec

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities – Fingerprint — University of Miami’s Research Profiles Sort by Weight Alphabetically Medicine & Life Sciences nintedanib 100% Idiopathic Pulmonary Fibrosis 75% Comorbidity 48% Elderly 42% Safety 36% Vital Capacity 22% Placebos 19% Therapeutics 5% Datasets 5% Source […]

Read more
13Dec

Medicina | Free Full-Text | Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Medicina | Free Full-Text | Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report

1. Introduction Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-associated interstitial lung disease (ILD) has been recognized as an important entity in patients with dermatomyositis-associated interstitial lung disease, especially rapidly progressive interstitial lung disease (RP-ILD) [1]. Anti-MDA5 antibody, first described in a Japanese cohort of patients with inflammatory myositis by Sato et al. in 2005, targets the […]

Read more
12Dec

Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction

Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory […]

Read more
10Dec

Faron Pharmaceuticals Says Cancer Drug Study Shows Kickstarted Immune Response

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Faron Pharmaceuticals Says Cancer Drug Study Shows Kickstarted Immune Response

By Joe Hoppe Faron Pharmaceuticals Oyj said Thursday that initial data analysis from a clinical trail shows its Bexmarilimab treatment starts immune responses in some cancer patients that haven’t traditionally benefited from current immunotherapy treatments. The biopharmaceutical company, which is listed in the U.K. and Finland, said patients with low baseline levels of inflammatory cytokines […]

Read more
7Dec

Get Well Soon | Clinical Trial: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Get Well Soon | Clinical Trial: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

PRIMARY OBJECTIVES: I. To estimate the proportion of patients with persistent or recurrent endometrial cancer, who survive progression-free without going on a subsequent therapy against the disease for at least 6 months and the proportion of patients who have objective tumor response (complete or pa… PRIMARY OBJECTIVES: I. To estimate the proportion of patients with […]

Read more
4Dec

IFN-gamma Products | Bio-Techne

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on IFN-gamma Products | Bio-Techne

IFN-gamma (Interferon-gamma) is the prototype proinflammatory cytokine and is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, […]

Read more
4Dec

Improving CAR-T cell therapies for cancer by targeting a protein ‘brake’

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Improving CAR-T cell therapies for cancer by targeting a protein ‘brake’

CAR-T cell therapy, which modifies a patient’s own T cells to recognize specific antigens on tumors, has proven effective in treating blood cancers. But the engineered immune cells have precious little time to proliferate in the body, which often limits their anti-tumor efficacy. Now, scientists at the Curie Institute in France have identified a potential […]

Read more
2Dec

Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver

Pirfenidone is a first-line drug for the treatment of idiopathic pulmonary fibrosis. The primary metabolic pathways of pirfenidone in humans are 5-hydroxylation and subsequent oxidation to 5-carboxylpirfenidone. The aims of this study were to determine the cytochrome P450 isoforms responsible for pirfenidone 5-hydroxylation and to evaluate their contributions in human liver microsomes (HLM). Among the […]

Read more
2Dec

Spandidos Publications

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Spandidos Publications

Related Articles The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells Enhancement of cisplatin-induced cytotoxicity by […]

Read more
29Nov

Characterization of Agapornis fischeri interferon gamma and its activity against beak and feather disease virus by Jui-Kai Chen

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Characterization of Agapornis fischeri interferon gamma and its activity against beak and feather disease virus by Jui-Kai Chen

This study sought to clone and sequence the interferon-γ (IFN-γ) gene of the Fischer’s lovebird parrot (Agapornis fischeri). Raw264.7 cells treated with the expressed IFN-γ protein exhibited an upregulation in inducible nitric oxide synthase protein expression and nitric oxide (NO) production coupled with increases in phagocytosis and pinocytosis, as well as an induction of interferon-stimulated […]

Read more
23Nov

DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on DiaSorin, MeMed Obtain CE Mark for High-Throughput Immune-Response Assay

NEW YORK ─ DiaSorin and MeMed on Tuesday announced they have obtained CE marking for a high-throughput, immune-response assay called Liaison MeMed BV and launched it in countries that accept the designation. The Liaison MeMed BV test is a fully automated, chemiluminescent immunoassay that uses host-response data to enable physicians to differentiate between bacterial and viral infections, […]

Read more
23Nov

Interferon-Gamma, Human Recombinant Protein [228-20144]

Posted by: admin Categories: Idiopathic Pulmonary Fibrosis
Comments Off on Interferon-Gamma, Human Recombinant Protein [228-20144]

Format: Sterile Filtered White lyophilized (freeze-dried) powder. Formulation: The protein was lyophilized from a 0.2 um filtered concentrated solution in PBS pH 4.5. Purity: Greater than 98.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE. Expressed Region: MQDPYVKEAE NLKKYFNAGH SDVADNGTLF LGILKNWKEE SDRKIMQSQI VSFYFKLFKN FKDDQSIQKS VETIKEDMNV KFFNSNKKKR DDFEKLTNYS VTDLNVQRKA IHELIQVMAE LSPAAKTGKR KRSQMLFQGR RASQ. Protein Name […]

Read more
« Older posts
Newer posts »